WO2019035335A1 - Procédé de collecte d'acides nucléiques, support pour liaison d'acides nucléiques, et kit de collecte d'acides nucléiques - Google Patents

Procédé de collecte d'acides nucléiques, support pour liaison d'acides nucléiques, et kit de collecte d'acides nucléiques Download PDF

Info

Publication number
WO2019035335A1
WO2019035335A1 PCT/JP2018/028130 JP2018028130W WO2019035335A1 WO 2019035335 A1 WO2019035335 A1 WO 2019035335A1 JP 2018028130 W JP2018028130 W JP 2018028130W WO 2019035335 A1 WO2019035335 A1 WO 2019035335A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
porous silica
silica particles
binding
volume
Prior art date
Application number
PCT/JP2018/028130
Other languages
English (en)
Japanese (ja)
Inventor
酒井　智弘
太志 原
哲也 小谷
信介 山▲崎▼
Original Assignee
Ａｇｃ株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP2017157978A external-priority patent/JP2020191785A/ja
Priority claimed from JP2017157968A external-priority patent/JP2020191784A/ja
Application filed by Ａｇｃ株式会社 filed Critical Ａｇｃ株式会社
Publication of WO2019035335A1 publication Critical patent/WO2019035335A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M1/00—Apparatus for enzymology or microbiology
    • C12M1/26—Inoculator or sampler
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/02—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material
    • B01J20/10—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/28—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof characterised by their form or physical properties
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/34—Regenerating or reactivating
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B33/00—Silicon; Compounds thereof
    • C01B33/113—Silicon oxides; Hydrates thereof
    • C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid

Definitions

  • the present invention relates to a nucleic acid recovery method, a nucleic acid binding carrier and a nucleic acid recovery kit.
  • infectious disease diagnostic kit one intended for a protein (antigen, antibody, etc.) has been used.
  • the accuracy is low except for a part of infectious diseases such as influenza, and in the case of targeting an antibody, false positive due to past infection. Therefore, in recent years, infectious disease diagnostic kits for nucleic acids have been studied. By targeting nucleic acid, an improvement in accuracy is expected.
  • the sample which is a biological sample contains various components, and it is necessary to isolate the nucleic acid from the sample for diagnosis.
  • a method of isolating nucleic acid from a biological sample there is known a method of adsorbing or binding nucleic acid to a carrier containing silica, removing components other than nucleic acid by washing, and eluting nucleic acid from the carrier.
  • Nucleic acid purification kits using this method have already been put to practical use, and silica membranes are widely used as carriers (eg, non-patent documents 1 to 3).
  • nucleic acid isolation methods do not always have high extraction rates of nucleic acids, and in the case of nucleic acids having a length of 10 5 bp or more in particular, they can not be extracted or extraction is low even if extraction is possible. there were.
  • the extraction rate is low, it is necessary to perform an amplification process for a long time using an expensive apparatus, which limits the facilities that can be implemented and also takes a long time.
  • An object of the present invention is to provide a method for recovering nucleic acid with high recovery rate by a simple operation even when nucleic acid is long, a carrier for binding to nucleic acid and a nucleic acid recovery kit suitably used for the recovery method.
  • the present invention provides a nucleic acid recovery method, a nucleic acid binding carrier and a nucleic acid recovery kit, having the following aspects [1] to [16].
  • [1] is a D 50 of 6 ⁇ 50 [mu] m particle size distribution based on volume, the pore volume determined by the BJH method is the 0.3 ⁇ 5 cm 3 / g, an average pore diameter determined by BJH method from 60 to A nucleic acid is bound to porous silica particles (hereinafter also referred to as porous silica particles I) having a thickness of 500 ⁇ to form a complex, A method for recovering nucleic acid, which comprises eluting and recovering the nucleic acid from the complex.
  • porous silica particles I porous silica particles
  • a nucleic acid is bound to a porous silica particle (hereinafter, also referred to as porous silica particle II) which is 5000 ⁇ to form a complex
  • a method for recovering nucleic acid which comprises eluting and recovering the nucleic acid from the complex.
  • [8] The method for recovering nucleic acid according to any one of [1] to [7], wherein the complex is washed before eluting the nucleic acid from the complex.
  • [9] The method for recovering a nucleic acid according to any one of [1] to [8], wherein the length of the nucleic acid is 10 5 to 10 11 bp.
  • a carrier for nucleic acid binding comprising porous silica particles of 5000 ⁇ .
  • nucleic acid recovery kit [16] The nucleic acid recovery kit according to any one of [12] to [15], further comprising a fourth container containing a washing solution for washing the complex in which the porous silica particles and the nucleic acid are bound.
  • nucleic acid recovery method of the present invention even when the nucleic acid is long, the nucleic acid can be recovered at a high recovery rate by a simple operation.
  • the nucleic acid binding carrier and the nucleic acid recovery kit of the present invention can be suitably used for the above recovery method, respectively.
  • FIG. 16 is a graph showing the relationship between D 50 of the porous silica particles I and DNA recovery in Examples 1 to 10 of Example A.
  • FIG. FIG. 16 is a graph showing the relationship between D 90 / D 10 of the porous silica particles I and the DNA recovery in Examples 1 to 10 of Example A.
  • FIG. FIG. 16 is a graph showing the relationship between the pore volume of porous silica particles I and the DNA recovery in Examples 1 to 10 of Example A.
  • FIG. 7 is a graph showing the relationship between the average pore size of porous silica particles I and the DNA recovery in Examples 1 to 10 of Example A. 7 is a graph showing the relationship between the specific surface area (SSA) of porous silica particles I and the DNA recovery in Examples 1 to 10 of Example A.
  • FIG. SSA specific surface area
  • FIG. 16 is a graph showing the relationship between D 50 of the porous silica particles II and the DNA recovery in Examples 12 to 26 of Example B.
  • FIG. FIG. 16 is a graph showing the relationship between D 90 / D 10 of the porous silica particles II and the DNA recovery in Examples 12 to 26 of Example B.
  • FIG. FIG. 16 is a graph showing the relationship between the pore volume of porous silica particles II and the DNA recovery in Examples 12 to 26 of Example B.
  • FIG. FIG. 16 is a graph showing the relationship between the average pore size of porous silica particles II and the DNA recovery in Examples 12 to 26 of Example B.
  • FIG. FIG. 16 is a graph showing the relationship between the specific surface area (SSA) of porous silica particles II and the DNA recovery in Examples 12 to 26 of Example B.
  • SSA specific surface area
  • D 50 is a particle diameter at a point of 50% in a cumulative volume distribution curve where the total volume of particle size distribution on a volume basis is 100%, that is, a volume based cumulative 50% diameter.
  • D 10 is the particle diameter at a point of 10% in the cumulative volume distribution curve where the total volume of particle size distribution on a volume basis is 100%, that is, the volume based cumulative 10% diameter.
  • D 90 is a particle diameter at a point of 90% in the cumulative volume distribution curve where the total volume of particle size distribution on a volume basis is 100%, that is, a volume-based cumulative 90% diameter.
  • the “particle size distribution on a volume basis” is obtained from the frequency distribution and the cumulative volume distribution curve measured by a laser scattering particle size distribution measuring apparatus (for example, a laser diffraction / scattering type particle size distribution measuring apparatus etc.). The measurement is carried out by sufficiently dispersing the powder in an aqueous medium by ultrasonic treatment or the like.
  • the “pore volume determined by the BJH method” is a pore volume determined from the adsorption isotherm by the BJH method. In the measurement of the adsorption isotherm, nitrogen gas is used as the adsorption gas.
  • the "average pore size determined by the BJH method” is an average pore size determined from the adsorption isotherm by the BJH method.
  • the “BJH method” is a method of determining mesopore diameter distribution by Barrett, Joyner and Halenda, which is one of methods for determining pore diameter distribution from adsorption isotherm.
  • the "pore volume determined by mercury porosimetry” is a pore volume measured using a mercury porosimeter.
  • the "average pore size determined by mercury porosimetry” is an average pore size measured using a mercury porosimeter.
  • a physical property value of mercury is a contact angle of 140 °, a surface tension of 480 dynes / cm, and a density of 13.5335 g / mL. Measurement conditions are a pressure of 50 mm Hg, an evacuation time of 5 minutes, an injection pressure of 1.49 psi, and an equilibration time of 10 seconds.
  • the “specific surface area” is a specific surface area determined from an adsorption isotherm by a BET (Brunauer, Emmet, Teller) method. In the measurement of the adsorption isotherm, nitrogen gas is used as the adsorption gas.
  • Silica purity is the ratio of the mass of the silica (SiO 2) with respect to the total weight of the porous silica particles. Silica purity is measured by the quasi-drug raw material standard 2006 "anhydrous silicic acid” determination method. “-” Indicating a numerical range is used in the meaning including the numerical values described before and after that as the lower limit value and the upper limit value.
  • the nucleic acid recovery method of the present invention comprises the following binding and elution steps. After the binding step, the following washing step may be further included before the elution step. Bonding step: a step of binding a nucleic acid to porous silica particles I or porous silica particles II to form a complex. Washing step: a step of washing the complex. Elution step: a step of eluting and recovering nucleic acid from the complex.
  • porous silica particles are used as a carrier for binding nucleic acid. Porous silica particles have silica present on their surface. The porous silica particles may further contain components other than silica (hereinafter, also referred to as other components).
  • the silica purity of porous silica particle 95 mass% or more is more preferable, and 98 mass% or more is especially preferable.
  • the upper limit of the silica purity is not particularly limited, and may be 100% by mass.
  • the other components may be eluted from the porous silica particles at the time of recovery of the nucleic acid to adversely affect the measurement.
  • covered the surface of the magnetic body with porous silica is expensive for a raw material and manufacture, and is expensive.
  • the porous silica particles are preferably not magnetic silica particles in terms of cost and chemical resistance.
  • the whole particle may be a particle which consists of porous silica.
  • D 50 is 6 ⁇ 50 [mu] m, preferably 6 ⁇ 45 ⁇ m, 7 ⁇ 30 ⁇ m are particularly preferred. If D 50 is within the above range, the nucleic acid recovery rate is excellent.
  • D 90 / D 10 is preferably 10 or less, more preferably 8 or less, particularly preferably 6 or less. If D 90 / D 10 is less than the upper limit, the nucleic acid recovery more excellent.
  • the lower limit of D 90 / D 10 is not particularly limited, and may be 1, for example.
  • D 90 is, for example, 10 to 100 ⁇ m
  • D 10 is, for example, 1 to 50 ⁇ m.
  • Pore volume of porous silica particles I is a pore volume determined by the BJH method, the range is 0.3 ⁇ 5cm 3 / g, preferably 0.4 ⁇ 3cm 3 / g, 0.5 Particular preference is given to ⁇ 2.5 cm 3 / g.
  • the pore volume of the porous silica particles II is a pore volume determined by mercury porosimeter, the range is 0.6 ⁇ 5cm 3 / g, preferably 0.6 ⁇ 4cm 3 / g, 0 6 to 2.5 cm 3 / g are particularly preferred. If the pore volume is equal to or more than the lower limit value, the nucleic acid recovery rate is excellent. If the pore volume is equal to or less than the upper limit value, the washability is excellent.
  • the average pore size of the porous silica particles I is an average pore size determined by the BJH method, and the range is 60 to 500 ⁇ , preferably 60 to 450 ⁇ , and particularly preferably 90 to 450 ⁇ . If the average pore diameter of the porous silica particles I is not less than the above lower limit value, the nucleic acid recovery rate is excellent. If the average pore diameter is equal to or less than the upper limit value, the recovery rate is excellent even for short nucleic acids.
  • the average pore size of the porous silica particles II is an average pore size determined by a mercury porosimeter, and the range is 200 to 5000 ⁇ , preferably 200 to 4000 ⁇ , and particularly preferably 200 to 2500 ⁇ . If the average pore diameter of the porous silica particles II is not less than the lower limit value and not more than the upper limit value, the nucleic acid recovery efficiency is excellent.
  • the specific surface area of porous silica particles I is a specific surface area as determined by BET method is preferably 150 ⁇ 1000m 2 / g, more preferably 150 ⁇ 800m 2 / g, particularly preferably 170 ⁇ 650m 2 / g.
  • the specific surface area of porous silica particles II is a specific surface area as determined by the BET method, preferably 8 ⁇ 400m 2 / g, more preferably 8 ⁇ 350m 2 / g, particularly preferably 8 ⁇ 300m 2 / g .
  • the specific surface area is equal to or more than the lower limit value, the nucleic acid recovery rate is more excellent.
  • the specific surface area is equal to or less than the upper limit value, the washability is excellent.
  • porous silica particles those having desired properties (D 50 , pore volume, average pore diameter, etc.) can be appropriately selected and used from commercially available porous silica particles.
  • Nucleic acid is a generic term for DNA (deoxyribonucleic acid) and RNA (ribonucleic acid).
  • the type of nucleic acid to be bound to the porous silica particle is not particularly limited, and may be DNA, RNA, or a mixture thereof.
  • the type and structure of DNA and RNA are not particularly limited.
  • the DNA may be single stranded DNA or double stranded DNA.
  • the nucleic acid may be nucleic acid derived from a eukaryote (animal, plant, insect, nematode, yeast, mold etc.) or nucleic acid derived from a prokaryote (bacteria such as E. coli, Bacillus subtilis, cyanobacteria, mycoplasma etc.) It may be a nucleic acid derived from an inanimate substance (virus, chloroplast, mitochondria, etc.).
  • the length of the nucleic acids is preferably 10 ⁇ 10 11 bp, more preferably from 10 5 ⁇ 10 11 bp, particularly preferably 10 5 ⁇ 10 9 bp.
  • the length of the nucleic acid targeted by the nucleic acid purification kit using a conventional silica membrane is usually 10 6 bp or less. The longer the nucleic acid, the lower the recovery, especially at 10 5 bp or more, the lower the recovery. It is considered that this is because as the nucleic acid becomes longer, the nucleic acid becomes strongly bound to the carrier and becomes difficult to elute. According to the recovery method of the present invention, even a nucleic acid having a length of 10 5 bp or more can be recovered with an excellent recovery rate.
  • the utility of the present invention is particularly high when the length of the nucleic acid is 10 5 bp or more. If the length of the nucleic acid is 10 11 bp or less, the nucleic acid recovery rate is more excellent.
  • the naturally occurring nucleic acid of 10 5 to 10 11 bp in length is DNA.
  • nucleic acids are bound to the porous silica particles to form a complex.
  • the bonding step can be carried out using known methods, except that the porous silica particles are used as a carrier.
  • a method for binding nucleic acid to porous silica particles a sample containing nucleic acid and a binding solution are mixed to obtain a mixed solution (hereinafter also referred to as a first mixed solution), and the first mixed solution and the pores are obtained. And a method of contacting with the porous silica particles.
  • a biological sample is used as a sample containing nucleic acid.
  • biological samples include blood, serum, puncture fluid, airway wiping fluid, urine, feces, pus, hair, nails and the like.
  • the binding solution is a solution having an action of binding a nucleic acid to the porous silica particles.
  • the action of the binding solution causes the nucleic acids in the sample to bind to the porous silica particles.
  • a chaotropic substance solution is used as the binding solution.
  • the nucleic acids are bound to the porous silica particles in the presence of a chaotropic substance solution.
  • the chaotropic substance generates chaotropic ions in a solvent such as water.
  • the action of the chaotropic ion facilitates binding of the nucleic acid to the porous silica particle.
  • chaotropic ions can change the secondary, tertiary or quaternary structure without changing the primary structure of proteins or nucleic acids. Therefore, by mixing the biological sample and the chaotropic substance solution, cells or the like containing the nucleic acid in the biological sample can be destroyed and the nucleic acid can be eluted. Therefore, the chaotropic substance solution also functions as an eluent for eluting nucleic acids from cells or the like in a biological sample.
  • chaotropic substances examples include guanidine thiocyanate, guanidine hydrochloride, sodium iodide, potassium iodide, sodium perchlorate, urea and the like.
  • the chaotropic substances may be used alone or in combination of two or more.
  • guanidine thiocyanate or guanidine hydrochloride is preferable in view of the strength of the chaotropic effect and the magnitude of the inhibitory effect on nucleolytic enzymes such as ribonuclease.
  • the concentration of the chaotropic substance in the binding solution may be set appropriately depending on the chaotropic substance, as long as sufficient chaotropic effect can be obtained, preferably 1.0 to 8.0 M, and the chaotropic substance is guanidine hydrochloride. 4.0 to 7.5 M is preferable, and 3.0 to 5.5 M is preferable when the chaotropic substance is guanidine thiocyanate.
  • the binding solution preferably contains a buffer.
  • the buffer is not particularly limited as long as it is generally used, and is not particularly limited, but one having a buffer ability near neutral, ie, pH 5.0 to 9.0 is preferable, for example, Tris-HCl buffer, TE Buffers (containing Tris and ethylenediaminetetraacetic acid (EDTA)), sodium tetraborate-hydrochloric acid buffer, potassium dihydrogenphosphate-sodium tetraborate buffer and the like can be mentioned.
  • the buffer concentration of the binding solution is preferably 1 to 500 mM in terms of solid content.
  • the pH of the binding solution is preferably 6.0 to 9.0. The pH is the value at 25 ° C.
  • the binding solution may further contain a surfactant for the purpose of breaking down cell membranes and denatured proteins contained in the cells.
  • the surfactant is not particularly limited as long as it is generally used for nucleic acid extraction from cells and the like, and examples thereof include polyoxyethylene alkyl phenyl ether surfactant (for example, triton surfactant), poly Nonionic surfactants such as oxyethylene sorbitan fatty acid ester surfactants (for example, Tween surfactants), anionic surfactants such as N-lauroyl sarcosine sodium, and the like can be mentioned.
  • One surfactant may be used alone, or two or more surfactants may be used in combination.
  • the surfactant concentration of the binding solution is preferably 1 to 500 mM, for example, in the case of a nonionic surfactant.
  • the binding solution may further contain a reducing agent in order to denature and inactivate proteins contained in the sample, particularly ribonuclease.
  • the reducing agent is not particularly limited as long as it is generally used for nucleic acid extraction from cells and the like, and examples thereof include 2-mercaptoethanol, dithiothreitol and the like.
  • the alcohol may be further mixed when mixing the sample and the binding solution.
  • Alcohol can promote the insolubilization of nucleic acids.
  • examples of the alcohol include ethanol, propanol, isopropanol, butanol and the like.
  • the binding solution may contain an alcohol beforehand.
  • the amount of alcohol mixed with the sample and the binding solution is, for example, an amount such that the content of alcohol in the first mixture is 10 to 90% by mass with respect to the sample It is.
  • the temperature condition at the time of mixing is, for example, 4 to 80.degree.
  • the mixing time varies depending on the mixing method, but is, for example, 0.1 to 60 minutes.
  • the first mixed solution Before contacting the first mixed solution with the porous silica particles, the first mixed solution is subjected to pretreatment such as centrifugation for reduction of components other than nucleic acids (solid impurities and the like). It is also good.
  • pretreatment such as centrifugation for reduction of components other than nucleic acids (solid impurities and the like). It is also good.
  • the conditions for centrifugation are, for example, 100 to 20000 rpm and 0.1 to 60 minutes.
  • the first mixed solution and the porous silica particles are mixed to obtain a mixed solution (hereinafter also referred to as a second mixed solution).
  • a method of recovering porous silica particles (that is, composite) from the liquid mixture hereinafter, also referred to as method (1)), or a flowable container (for example, a porous member in which porous silica particles are retained so as not to flow out of the container)
  • a method (hereinafter, also referred to as method (2)) or the like in which the first mixed solution is passed through a column or the like can be mentioned.
  • the contact temperature at the time of contacting the first mixed solution with the porous silica particles is, for example, 4 to 80 ° C., and the contact time is, for example, 0.1 to 60 minutes.
  • the amount of porous silica particles mixed with the first liquid mixture is preferably 2 to 200 parts by mass with respect to 100 parts by mass of the first liquid mixture.
  • the time from when the first liquid mixture and the porous silica particles are mixed to when the porous silica particles are recovered from the second liquid mixture corresponds to the contact time.
  • the second mixed liquid may be stirred or the like.
  • various solid-liquid separation methods such as centrifugation and filtration can be used.
  • the second mixed solution is put in the upper part of the container divided up and down by a filter, and it is made to flow by centrifugation, suction or the like, and the porous silica particles remaining on the filter are recovered.
  • the method (2) may be, for example, a method in which the first mixed solution is put in the container, held for an arbitrary time (contact time), and then discharged from the container.
  • the amount of the first liquid mixture contained in the container is, for example, preferably 50 to 5000 parts by mass with respect to 100 parts by mass of the porous silica particles. While holding the first mixed solution in the container, stirring or the like may be performed.
  • the method for discharging the first mixed solution from the container is not particularly limited, and examples thereof include centrifugation and suction.
  • washing step the complex in which the porous silica particles and the nucleic acid are bound obtained in the binding step is washed.
  • Components other than nucleic acids proteins, saccharides, lipids, etc.
  • the washing may be performed once or twice or more.
  • the washing solution used for washing is not particularly limited as long as it does not elute nucleic acid from the complex and can promote the detachment of components other than nucleic acid.
  • cleaning liquid a chaotropic substance solution, alcohol, its aqueous solution etc. are mentioned, for example.
  • the chaotropic substance solution may be the same as that described above for the binding solution, and examples include 4.0 to 7.5 M guanidine hydrochloride solution.
  • the chaotropic substance solution may contain a buffer, a surfactant, a reducing agent and the like.
  • As the above-mentioned alcohol, ethanol, propanol, isopropanol, butanol and the like are preferable, and ethanol is particularly preferable.
  • the alcohol concentration of the alcohol or its aqueous solution is preferably 40 to 100% by mass, and more preferably 60 to 100% by mass. If the alcohol concentration is above the lower limit value, it is difficult for the nucleic acid to elute.
  • washing solution a chaotropic substance solution and an alcohol or an aqueous solution thereof may be used in combination.
  • washing with a chaotropic substance solution may be followed by washing with an alcohol or an aqueous solution thereof.
  • two or more kinds of alcohols having different alcohol concentrations or their aqueous solutions may be used in combination.
  • the method of washing the complex is not particularly limited.
  • a method of recovering a complex from a third liquid mixture by obtaining a mixed liquid (hereinafter also referred to as a third mixed liquid) by mixing the complex and the washing liquid recovered in the method (1) in the bonding step a method (hereinafter, also referred to as method (2 ′)), etc., in which a cleaning solution is passed through a container after the first mixed solution is discharged in the method (2) in the method (1 ′) Can be mentioned.
  • the temperature condition at the time of washing is preferably 4 to 80.degree.
  • the washing time per wash is preferably 0.1 to 60 minutes.
  • the amount of the washing solution mixed with the complex in one washing is preferably 10 to 10000 parts by mass with respect to 100 parts by mass of the complex.
  • the time from when the complex and the washing liquid are mixed to when the complex is recovered from the third mixed solution corresponds to the washing time. During this time, the second mixed liquid may be stirred or the like.
  • the same method as the method of recovering porous silica particles from the second mixed solution can be mentioned.
  • the method (2 ′) may be, for example, a method of putting a cleaning solution into the container, holding it for an arbitrary time (cleaning time), and then discharging it from the container.
  • the amount of the washing solution contained in the container is preferably 10 to 10000 parts by mass with respect to 100 parts by mass of the complex. While holding the cleaning solution in the container, stirring or the like may be performed.
  • a method of discharging the cleaning liquid from the container the same method as the method of discharging the first mixed liquid from the container may be mentioned.
  • the complex may be dried.
  • a drying method a thermostat etc. are mentioned, for example.
  • the drying temperature is 30 to 80 ° C.
  • the drying time is 0.1 to 3000 minutes.
  • the nucleic acid is eluted from the complex after the binding step or the washing step to recover the nucleic acid.
  • the elution may be performed once or twice or more.
  • the elution step can be carried out using a known method. For example, there is a method in which the complex is brought into contact with the eluate, and then the eluate is recovered.
  • the eluate is a solution having an action of eluting nucleic acids bound to the porous silica particles.
  • the action of the eluate elutes the nucleic acid from the complex to obtain an eluate containing the nucleic acid.
  • TE buffer 10 mM Tris-hydrochloride, 1.0 mM EDTA, pH 8.0
  • the method of bringing the complex into contact with the elution solution and then recovering the elution solution there is no particular limitation on the method of bringing the complex into contact with the elution solution and then recovering the elution solution.
  • the complex recovered in the method (1) in the binding step or the complex washed in the method (1 ′) in the washing step and the eluate are mixed and a mixed solution (hereinafter also referred to as a fourth mixed solution) ) And removing the complex (that is, porous silica particles) from which the nucleic acid is eluted from the fourth mixture (hereinafter, also referred to as method (1 ′ ′)), in the binding step in the method (2)
  • a method hereinafter, also referred to as method (2 ′ ′) in which the eluate is passed through a container after discharging the first liquid mixture or a container after discharging the washing liquid by the method (2 ′) in the washing step Can be mentioned.
  • the amount of eluate mixed with the complex is, for example, 10 to 10000 parts by mass with respect to 100 parts by mass of the complex.
  • the time from when the complex and the eluate are mixed to when the porous silica particles are recovered from the fourth mixture corresponds to the contact time. During this time, the fourth liquid mixture may be stirred or the like.
  • various solid-liquid separation methods such as centrifugation and filtration can be used.
  • Method (2 ′ ′) may be, for example, a method of putting the eluate into the container, holding it for an arbitrary time (contact time), and then discharging it from the container.
  • the amount of eluate contained in the container is, for example, 10 to 10000 parts by mass with respect to 100 parts by mass of the complex. While holding the eluate in the container, stirring or the like may be performed.
  • a method of discharging the eluate from the container the same method as the method of discharging the first mixed liquid from the container may be mentioned.
  • D 50 is 6 ⁇ 50 [mu] m
  • a pore volume determined by the BJH method is 0.3 ⁇ 5cm 3 / g
  • average pore diameter as determined by the BJH method Porous silica particles having a diameter of 60 to 500 ⁇ , or having a D 50 of 6 to 50 ⁇ m, a pore volume of 0.6 to 5 cm 3 / g as determined by mercury porosimetry, and an average pore diameter as determined by mercury porosimetry Since porous silica particles of 200 to 5000 ⁇ are used, nucleic acids can be recovered with high recovery rate even when the nucleic acids are long.
  • the nucleic acid can be recovered only by binding the nucleic acid to the porous silica particle and eluting it, and the operation is simple.
  • the binding efficiency of the nucleic acid to the porous silica particle in the binding step and the compounding in the elution step because the D 50 , the pore volume and the average pore diameter are in the above ranges
  • nucleic acid can be recovered with high recovery rate. As a reason for the high binding efficiency, it is considered that a part of the nucleic acid easily fits into the pores opened on the surface of the porous silica particle.
  • the reason why the elution efficiency is high is that the contact area with the nucleic acid is relatively reduced by the pores opened on the surface of the porous silica particles, and the individual pores are opened at a plurality of locations, When the nucleic acid fitted in the pore is detached, it is conceivable that the elution solution wraps around from inside the pore and the nucleic acid is easily detached.
  • the nucleic acid recovery kit of the present invention comprises a first container containing the porous silica particles described above, and a second container containing a binding solution for binding nucleic acids to the porous silica particles.
  • the nucleic acid recovery kit of the present invention may further include a third container containing an eluate for eluting the nucleic acid from the complex in which the porous silica particles and the nucleic acid are bound, as necessary.
  • the nucleic acid recovery kit of the present invention may further include a fourth container containing a washing solution for washing the complex in which the porous silica particles and the nucleic acid are bound, as necessary.
  • the nucleic acid recovery kit of the present invention can be used in the above-described method of recovering a nucleic acid of the present invention.
  • the bonding step can be carried out, for example, using porous silica particles contained in a first container and a binding liquid contained in a second container. If the third container is further provided, the elution step can be further performed using the eluate contained in the third container. When the fourth container is further provided, the washing step can be further performed using the washing liquid stored in the fourth container.
  • the porous silica particles contained in the first container When used in the bonding step, the porous silica particles may be removed from the first container, and the bonding step may be performed in another container. The bonding step may be performed in the first container while the particles are contained in the first container.
  • the binding solution contained in the second container includes the binding solution mentioned in the binding step, and a chaotropic substance solution is preferable.
  • a chaotropic substance solution is preferable.
  • the binding solution contained in the second container may be diluted with a solvent such as water.
  • Examples of the eluate contained in the third container include the eluate mentioned in the elution step.
  • it may be diluted with a solvent such as water.
  • the washing liquid contained in the fourth container includes the washing liquid mentioned in the washing step.
  • solvent such as water.
  • Example A With respect to the following porous silica particles 1 to 10, the particle size distribution, pore volume, average pore diameter and specific surface area were determined according to the following evaluation method, and nucleic acids (DNA) were further obtained based on Examples 1 to 11 below.
  • ⁇ Evaluation method ⁇ (Particle size distribution)
  • the porous silica particles are sufficiently dispersed in water by ultrasonication, and measurement is performed using a laser diffraction / scattering particle size distribution measuring device (MT-3300EX, manufactured by Nikkiso Co., Ltd.) to obtain frequency distribution and cumulative volume distribution curve. Volume-based particle size distribution was obtained. From the cumulative volume distribution curve obtained was determined D 10, D 50, D 90 , D 90 / D 10.
  • Porous silica particle 1 manufactured by AGC S.I. Tech., Model number: L-52.
  • Porous silica particle 2 manufactured by AGC S.I. Tech., Model number: L-203.
  • Porous silica particle 3 manufactured by AGC S.I. Tech., Model number: EP-DM-20-120A.
  • Porous silica particles 4 manufactured by Osaka Soda, model number: SP-120-20P.
  • Porous silica particles 5 manufactured by Osaka Soda, model number: IR-60-25 / 40.
  • Porous silica particles 6 manufactured by Fuji Silysia, model number: SMB100-20.
  • Porous silica particles 7 manufactured by AGC S.I. Tech., Model number: Sun Outdoor.
  • Porous silica particles 8 manufactured by AGC S.I. Tech., Model number: NP-200.
  • Porous silica particles 9 manufactured by Fuji Silysia, model number: BW-820MH.
  • Porous silica particles 10 manufactured by Fuji Silysia, model number: MB100-75 / 200.
  • Binding solution Adsorption buffer (Composition: 50 mM Tris-hydrochloride, 5.0 M guanidine thiocyanate, 20 mM EDTA, 1.2% by mass polyethylene) attached to the nucleic acid extraction kit (Qiagen, trade name: DNeasy Blood tisue kit) Glycol mono-p-isooctyl phenylene ether).
  • Washing solution 1 Washing buffer 1 attached to the nucleic acid extraction kit.
  • Washing solution 2 Washing buffer 2 attached to the nucleic acid extraction kit.
  • Eluent Elution buffer supplied with the above nucleic acid extraction kit.
  • Human genome solution manufactured by Promega, product name human genomic DNA G3041, containing DNA approximately 3 ⁇ 10 9 base pairs in length, DNA concentration 200 ⁇ g / mL.
  • E. coli genome solution prepared by treating a culture solution of E. coli DH5 ⁇ using Sigma-Aldrich, product name GenElute Plasmid Miniprep Kit, containing DNA of about 4.65 ⁇ 10 6 base pairs in length, 50 ⁇ g / DNA concentration mL.
  • Tip column Two pipette tips (manufactured by BioPointe Scientific, trade name: Pipette tip 1250 ⁇ l) are each cut into two along the circumferential direction, and the portion including the tip of the pipette tip (hereinafter also referred to as “part A”) And a portion including the rear end of the pipette tip (hereinafter, also referred to as “portion B”). At this time, the cutting position (the distance from the tip to the cutting position) of each of the two pipette tips was changed. Because the pipette tip has a smaller diameter toward the tip, the inner diameters at the cutting positions of the two pipette tips are different.
  • the opening at the rear end of the longer part of the two parts A obtained from each of the two pipette tips (the one with the larger internal diameter at the cutting position) was covered with a 1 ⁇ m pore size polytetrafluoroethylene (PTFE) filter .
  • PTFE polytetrafluoroethylene
  • Example 1 Using a human genome solution or an E. coli genome solution as a sample, the nucleic acid was recovered from the sample according to the following procedure, and the recovery rate of nucleic acid (DNA) was determined. The results are shown in Table 1. First, 220 ⁇ L of a sample, 200 ⁇ L of a binding solution and 200 ⁇ L of 100% by mass ethanol were added to a 1.5 mL Eppendorf tube, and mixed to obtain a first mixed solution. Next, 20 mg of porous silica particles shown in Table 1 were added to 620 ⁇ L of the first mixed solution, and mixed to obtain a second mixed solution.
  • the whole amount of the second mixed solution is transferred to the chip column, and the porous silica particles are collected on the filter of the chip column by centrifuging under the conditions of 20 ° C. for 2 minutes at 3500 rpm using a centrifuge.
  • the filtrate was discarded, 500 ⁇ L of washing solution 1 was added to the tip column, and centrifuged under the same conditions as described above.
  • the filtrate was discarded, 500 ⁇ L of washing solution 2 was added to the tip column, and centrifuged under the same conditions as described above. Thereafter, the filtrate was discarded and centrifuged at 3500 rpm for 7 minutes at 20 ° C.
  • 200 ⁇ L of the eluate was added to the chip column, allowed to stand for 1 minute, and centrifuged under conditions of 3500 rpm, 2 minutes, and 20 ° C.
  • the obtained filtrate was used as a nucleic acid extract.
  • Example 11 Using a commercially available nucleic acid extraction kit (manufactured by Qiagen, trade name: DNeasy Blood tisue kit) using a human genome solution or E. coli genome solution as a sample, the nucleic acid is extracted according to the protocol and a nucleic acid extract I got With respect to the obtained nucleic acid extract, in the same manner as in Examples 1 to 10, the nucleic acid was recovered from the sample by the following procedure, and the recovery rate of the nucleic acid (DNA) was determined. The results are shown in Table 1.
  • the D 10 , D 50 , D 90 , D 90 / D 10 , silica (SiO 2 ) purity, specific surface area, pore volume, and average pore diameter of the porous silica particles used in Examples 1 to 10 are shown in Table 1. .
  • the porous silica particles 3 and 8 were measured about the silica purity, the silica purity of the other porous silica particle is all considered to be 98 mass% or more.
  • taken ordinate DNA recovery rate when the human genome solution as a sample D 50 of the porous silica particles, D 90 / D 10 pore volume, average pore diameter or the specific surface area (SSA Figures 1 to 5 show graphs in which the horizontal axis is taken). In each graph, the results of Examples 1 to 6 are shown as Examples, and the results of Examples 7 to 10 are shown as Comparative Examples.
  • Example 1 the recovery of nucleic acid was high.
  • Example 7 since the porous silica particles had a D 50 of less than 6 ⁇ m and a pore volume of less than 0.3 cm 3 / g, the nucleic acid recovery rate was poor.
  • Example 8 since the pore volume of the porous silica particles was less than 0.3 cm 3 / g and the average pore diameter was less than 60 ⁇ , the recovery rate of nucleic acid was inferior.
  • Example 9 since the D50 of the porous silica particles is greater than 50 ⁇ m, the pore volume is less than 0.3 cm 3 / g, and the average pore diameter is less than 60 ⁇ , the nucleic acid recovery rate is poor.
  • Example 10 the recovery rate of the nucleic acid was poor because the D 50 of the porous silica particles was larger than 50 ⁇ m.
  • Example B The particle size distribution, pore volume, average pore diameter and specific surface area of the following porous silica particles 12 to 26 were determined according to the following evaluation method, and nucleic acids (DNA) were further obtained based on Examples 12 to 27 of Example B below.
  • the evaluation methods and materials used in each example are shown below.
  • Pore volume and average pore size were measured using a mercury porosimeter (manufactured by Mirometrics, AutoPore IV 9500).
  • the physical properties of mercury used were a contact angle of 140 °, a surface tension of 480 dynes / cm, and a density of 13.5335 g / mL.
  • the measurement conditions were a pressure of 50 mmHg, an evacuation time of 5 minutes, an injection pressure of 1.49 psi, and an equilibration time of 10 seconds.
  • Porous silica particles 12 manufactured by AGC S.I. Tech., Model number: L-52.
  • Porous silica particles 13 manufactured by AGC S.I. Tech., Model number: EP-DM-10-1000AW.
  • Porous silica particle 16 AG manufactured by SSI Tech, model number: L-203.
  • Porous silica particles 18 manufactured by Osaka Soda, model number: SP-1000-20.
  • Example A The same type as in Example A was used for the binding solution, washing solution 1, washing solution 2, eluate, human genome solution, E. coli genome solution and chip column.
  • Example 12 to 26 Using a human genome solution or E. coli genome solution as a sample, the nucleic acid was recovered from the sample in the same manner as in Examples 1 to 10 of Example A, and the recovery rate of nucleic acid (DNA) was determined. The results are shown in Table 2.
  • Example 27 shows the results of Example 11 in Table 1 of Example A. With respect to the obtained nucleic acid extract, in the same manner as in Examples 12 to 26, the nucleic acid was recovered from the sample by the following procedure, and the recovery rate of the nucleic acid (DNA) was determined. The results are shown in Table 2.
  • the D 10 , D 50 , D 90 , D 90 / D 10 , silica (SiO 2 ) purity, specific surface area, pore volume, and average pore diameter of the porous silica particles used in Examples 12 to 26 are shown in Table 2. . Although only the porous silica particles 13 to 15 and 22 to 23 were measured as to the silica purity, it is considered that the silica purity of the other porous silica particles is also 98 mass% or more.
  • the DNA recovery rate when using a human genome solution as a sample is indicated on the vertical axis as D 50 , D 90 / D 10 , pore volume, average pore diameter or specific surface area (SSA) of porous silica particles. 6 to 10 show graphs in which the abscissa axis is taken). In each graph, the results of Examples 12 to 21 are shown as Examples, and the results of Examples 22 to 27 are shown as Comparative examples.
  • Example 12-21 the recovery of nucleic acid was high.
  • Example 22 since the porous silica particles had a D 50 of less than 6 ⁇ m, the nucleic acid recovery rate was poor.
  • Example 23 since the pore volume of the porous silica particles is less than 0.6 cm 3 / g and the average pore diameter is less than 200 ⁇ , the recovery rate of the nucleic acid is poor.
  • Examples 24 to 26 since the porous silica particles had a D 50 of more than 50 ⁇ m, the recovery rate of nucleic acid was poor.

Abstract

L'invention fournit un procédé destiné à collecter des acides nucléiques selon un rendement élevé par une manipulation simple, y compris dans le cas d'acides nucléiques longs, et un support pour liaison d'acides nucléiques ainsi qu'un kit de collecte d'acides nucléiques mettant en œuvre ledit procédé de collecte de manière adéquate. Plus précisément, l'invention concerne un procédé de collecte d'acides nucléiques selon lequel un complexe est formé par liaison à un acide nucléique soit de particules de silice poreuses de répartition granulométrique (Ｄ５０) sur la base du volume comprise entre ６ et ５０μｍ, de volume de pore obtenu selon un procédé BJH compris entre ０,３ et ５ｃｍ３／ｇ, et de diamètre de pore moyen obtenu selon le procédé BJH compris entre ６０ et ５００Å, soit de particules de silice poreuses de répartition granulométrique (Ｄ５０) sur la base du volume comprise entre ６ et ５０μｍ, de volume de pore obtenu par porosimétrie au mercure compris entre ０,６ et ５ｃｍ３／ｇ, et de diamètre de pore moyen obtenu par porosimétrie au mercure compris entre ２００ et ５０００Å. Enfin, selon le procédé de l'invention, ledit acide nucléique est soumis à une élution vis-à-vis dudit complexe et est collecté.
PCT/JP2018/028130 2017-08-18 2018-07-26 Procédé de collecte d'acides nucléiques, support pour liaison d'acides nucléiques, et kit de collecte d'acides nucléiques WO2019035335A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2017157978A JP2020191785A (ja) 2017-08-18 2017-08-18 核酸の回収方法、核酸結合用担体および核酸回収キット
JP2017-157978 2017-08-18
JP2017157968A JP2020191784A (ja) 2017-08-18 2017-08-18 核酸の回収方法、核酸結合用担体および核酸回収キット
JP2017-157968 2017-08-18

Publications (1)

Publication Number Publication Date
WO2019035335A1 true WO2019035335A1 (fr) 2019-02-21

Family

ID=65362260

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/028130 WO2019035335A1 (fr) 2017-08-18 2018-07-26 Procédé de collecte d'acides nucléiques, support pour liaison d'acides nucléiques, et kit de collecte d'acides nucléiques

Country Status (1)

Country Link
WO (1) WO2019035335A1 (fr)

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505724A (ja) * 1993-08-30 1997-06-10 プロメガ・コーポレイシヨン 核酸精製用組成物及び方法
JPH11313670A (ja) * 1997-12-25 1999-11-16 Tosoh Corp 磁性担体、その製造方法及びこれを用いた核酸抽出方法
JP2000300262A (ja) * 1999-04-14 2000-10-31 Toyobo Co Ltd 粒子担体を使用した核酸の抽出方法
JP2003507049A (ja) * 1999-08-20 2003-02-25 プロメガ コーポレイション Ｄｎａの同時単離及び定量化
US20050287583A1 (en) * 1997-01-21 2005-12-29 Promega Corporation Methods and kits for isolating biological target materials using silica magnetic particles
JP2007286226A (ja) * 2006-04-14 2007-11-01 Sumitomo Osaka Cement Co Ltd 防眩部材
JP2008072987A (ja) * 2006-09-22 2008-04-03 Sony Corp 微小流路、核酸回収装置、並びに核酸回収方法
JP2008220260A (ja) * 2007-03-13 2008-09-25 Hitachi Metals Ltd 磁性粒子の磁気分離方法
JP2009092592A (ja) * 2007-10-11 2009-04-30 Toyobo Co Ltd 核酸固定用基材、核酸固定用基材の製造方法、核酸検査用デバイス、核酸検査用デバイスの製造方法、並びに核酸検査方法
US20090221809A1 (en) * 2005-12-09 2009-09-03 Sud-Chemie Ag Method for the sorption of at least one nucleic acid-activated phyllosilicates
JP2014009215A (ja) * 2012-07-02 2014-01-20 Nof Corp 三級アミノ基含有脂質の製造方法
JP2014526973A (ja) * 2011-09-15 2014-10-09 インストラクション・ゲーエムベーハー 有機分子の精製のための陰イオン基または脱プロトン化基を有する芳香族環系をその表面に含む吸着材
US20150275269A1 (en) * 2012-10-26 2015-10-01 The Emerther Company Method for purifying nucleic acid and kit
JP2017003527A (ja) * 2015-06-15 2017-01-05 富士シリシア化学株式会社 親水性相互作用クロマトグラフィー用充填剤、及び親水性化合物の分離方法

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09505724A (ja) * 1993-08-30 1997-06-10 プロメガ・コーポレイシヨン 核酸精製用組成物及び方法
US20050287583A1 (en) * 1997-01-21 2005-12-29 Promega Corporation Methods and kits for isolating biological target materials using silica magnetic particles
JPH11313670A (ja) * 1997-12-25 1999-11-16 Tosoh Corp 磁性担体、その製造方法及びこれを用いた核酸抽出方法
JP2000300262A (ja) * 1999-04-14 2000-10-31 Toyobo Co Ltd 粒子担体を使用した核酸の抽出方法
JP2003507049A (ja) * 1999-08-20 2003-02-25 プロメガ コーポレイション Ｄｎａの同時単離及び定量化
US20090221809A1 (en) * 2005-12-09 2009-09-03 Sud-Chemie Ag Method for the sorption of at least one nucleic acid-activated phyllosilicates
JP2007286226A (ja) * 2006-04-14 2007-11-01 Sumitomo Osaka Cement Co Ltd 防眩部材
JP2008072987A (ja) * 2006-09-22 2008-04-03 Sony Corp 微小流路、核酸回収装置、並びに核酸回収方法
JP2008220260A (ja) * 2007-03-13 2008-09-25 Hitachi Metals Ltd 磁性粒子の磁気分離方法
JP2009092592A (ja) * 2007-10-11 2009-04-30 Toyobo Co Ltd 核酸固定用基材、核酸固定用基材の製造方法、核酸検査用デバイス、核酸検査用デバイスの製造方法、並びに核酸検査方法
JP2014526973A (ja) * 2011-09-15 2014-10-09 インストラクション・ゲーエムベーハー 有機分子の精製のための陰イオン基または脱プロトン化基を有する芳香族環系をその表面に含む吸着材
JP2014009215A (ja) * 2012-07-02 2014-01-20 Nof Corp 三級アミノ基含有脂質の製造方法
US20150275269A1 (en) * 2012-10-26 2015-10-01 The Emerther Company Method for purifying nucleic acid and kit
JP2017003527A (ja) * 2015-06-15 2017-01-05 富士シリシア化学株式会社 親水性相互作用クロマトグラフィー用充填剤、及び親水性化合物の分離方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GUNAL, G. ET AL.: "Human genomic DNA isolation from whole blood using a simple microfluidic system with silica- and polymer-based stationary phases", MATERIALS SCIENCE AND ENGINEERING C, vol. 74, 10 January 2017 (2017-01-10), pages 10 - 20 *
SAKASHITA, SHIZUKA: "Fundamental Powder Technology for Engineer Related to Colour Material Field : Chap. 1 Physical Property of Particle and Powder", J. JPN. SOC. COLOUR MATER., vol. 78, 2005, pages 168 - 184 *
ZHANG, L. ET AL.: "Preparation of porous magnetic silica microspheres and their application in genomic deoxyribonucleic acids extraction", CHINESE JOURNAL OF ANALYTICAL CHEMISTRY, vol. 34, no. 7, 2006, pages 923 - 926, XP022857778, DOI: doi:10.1016/S1872-2040(06)60043-1 *
ZHANG, Z. ET AL.: "Synthesis of novel porous magnetic silica microspheres as adsorbents for isolation of genomic DNA", BIOTECHNOLOGY PROGRESS, vol. 22, no. 2, 2006, pages 514 - 518, XP002440337, DOI: doi:10.1021/bp050400w *

Similar Documents

Publication Publication Date Title
JP7370987B2 (ja) 固液相系を用いて核酸を単離して精製するための方法
AU2002333673B2 (en) Isolation and purification of nucleic acids
JP2012502632A (ja) スモールｒｎａの単離法
EP1911844A1 (fr) Procédé et kit pour isoler des acides nucléiques
JP6562389B2 (ja) 核酸の精製方法
AU2015314928B2 (en) Sorbent material for separating bio-macromolecules
JP2020536579A (ja) 短い核酸断片の単離、精製及び／又は濃縮のために水性二相系を使用する方法
JP2006311803A (ja) 核酸精製方法、及び核酸精製器具
JP2006517225A (ja) 核酸抽出のための生物学的試料の化学処理および該処理用のキット
US8685742B2 (en) Apparatus and method for the more efficient isolation of nucleic acids
JP2007244375A (ja) リボ核酸の分離精製方法
US8586350B2 (en) Mechanism of separating and purifying DNA and the like
US20230257733A1 (en) Method for isolating nucleic acid
JP4297148B2 (ja) 核酸回収装置及び核酸回収方法
WO2019035335A1 (fr) Procédé de collecte d'acides nucléiques, support pour liaison d'acides nucléiques, et kit de collecte d'acides nucléiques
JP6737179B2 (ja) 核酸の分離精製方法および固相担体、デバイス、キット
JP2020191785A (ja) 核酸の回収方法、核酸結合用担体および核酸回収キット
JP2020191784A (ja) 核酸の回収方法、核酸結合用担体および核酸回収キット
EP3124608B1 (fr) Procédé et réactif d'extraction d'acide nucléique
JP5880626B2 (ja) 簡便かつ迅速な核酸抽出方法
JP4482517B2 (ja) 銀ナノ粒子を利用した標的物質の精製方法
JPH11262387A (ja) 核酸結合性磁性担体およびそれを用いた核酸単離方法
JP4690656B2 (ja) 核酸の分離精製方法及び分離吸着体
JP2010200661A (ja) 簡便かつ迅速な核酸抽出方法
RU2653130C1 (ru) Магнитный сорбент, способ его получения и способ выделения молекул нуклеиновых кислот

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18846166

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 18846166

Country of ref document: EP

Kind code of ref document: A1